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ABSTRACT  
Objective: Piroxicam is a poor water soluble drug; an effort had been made to enhance their dissolution rate through formulating it as a 
microsponge and then fabricated as a tablet for oral administration.  
Methods: Piroxicam microsponges were prepared by quasi-emulsion solvent diffusion method using Eudragit RS100, RL100, S100 with different 
drug-polymer ratios, three different types of inner phase solvent were used, along with various volumes of the selected organic solvent, the 
prepared formulas were examined for it its production yield, loading efficiency, particle size and in vitro drug release for formulas have excellent 
physical properties. Optimum formula that had fast release profile was further fabricated into a tablet using direct compression method, two types 
of disintegrants along with two different amounts were used, also the addition of microcrystalline cellulose was examined.  
Results: The results showed that as the ratio of drug to polymer was increased, the production yield and loading efficiency were enhanced, but the 
particle size had an inverse relationship. Among the three types of solvent, ethanol was most preferable one; 5 ml of ethanol was most favorable. 
PF13 (containing Eudragit RS100) have the rapid release profile. No any chemical interaction was observed, microsponge with spherical shape, 
porous structure was obtained. The prepared tablets have acceptable physical parameters. A dramatic enhancement in the dissolution rate as 
compared with the pure piroxicam tablet was shown, as well as release profile follows Hixson-Crowell kinetic with non Fickian diffusion. 
Conclusion: Microsponge may represent a promising way to increase the dissolution rate of poorly water-soluble drug. 
Keywords: Piroxicam, Microsponge, Eudragit RS100, Loading efficiency, Crospovidone.  
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INTRODUCTION  
The oral route is the most desirable way for drug administration due 
to its convenience and good patient compliance. A drug from its 
dosage form is absorbed from the gastrointestinal tract, only when it 
is dissolved in gastric and intestinal fluids. Following administration, 
poorly water soluble drugs tend to be eliminated from the 
gastrointestinal tract before being fully dissolved and absorbed into 
the blood circulation, which results in a slower onset of action or a 
trouble in achieving the required therapeutic level. During the last 
decade, more than 40% of the new chemical entities launched in the 
U. S. pharmaceutical market faced the problem of adequate aqueous 
solubility [1]. When the bioavailability of a drug substance is limited 
by its poor solubility, enhancing the dissolution may improve 
bioavailability. However, when the bioavailability is limited by the 
intestinal permeability, faster dissolution is not expected to increase 
bioavailability. Therefore, of the BCS classes, class II drug molecules 
are the most promising to show enhancement in the bioavailability 
as a result of increased solubility, so aqueous solubility of a drug 
make it in a critical limitation to its oral absorption [2].  
Microsponge technology was developed by Won in 1987 and the 
original patents were assigned to advanced polymer system [3]. 
Micro sponges are porous microsphere having interconnected voids 
of particle size range 5-300μm. They are uniform, spherical 
polymeric particles. Microsponge delivery system (MDS) is a unique 
technology for controlling delivery of drug. MDS technology has 
been introduced in topical drug products to facilitate a controlled 
release of active drug into the skin in order to reduce the systemic 
exposure and minimize local cutaneous reactions to the active drug 
moieties [4]. Recently microsponge system has been shown to 
increase the rate of solubilization of poorly water-soluble drugs by 
entrapping such drugs in the microsponge system's pores. Because 
these pores are very small, so the drug moiety is reduced to 
microscopic particles and so significantly increase surface area thus 
greatly enhance the rate of solubilization. Piroxicam (PIR) is an 
oxicam derivative non-steroidal anti-inflammatory drug (NSAID), by 
interfering with the synthesis of prostaglandins, PIR produces its 
effects. The therapeutic action of NSAID is thought to occur by the 
inhibition of the cyclooxygenase enzyme. Piroxicam is an antipyretic, 
analgesic and anti-inflammatory agent used in the treatment of 
rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, 
dysmenorrhea, and acute gout [5]. The aim of this study focusing on 
the preparation of piroxicam microsponges in order to enhance the 
solubility and dissolution rate, subsequent evaluation of different 
variables affecting the Microsponge formulation, select the optimum 
one that will be further incorporated into tablet and then study the 
effect of different concentration and composition of additives on the 
release profile of piroxicam from the prepared tablet. 
MATERIALS AND METHODS  
Materials  
Piroxicam was kindly supplied from al-Safa drug industry, Iraq, 
Eudragit RS 100, Eudragit RL100; Eudragit S100 was purchased 
from Rhom Pharma Germany. Dichloromethane was obtained from 
GCC Analytical Reagent, UK. Ethanol was purchased from Sigma-
Aldrich, Germany. Methanol was obtained from Thomas Baker 
chemical, Mumbai, India. Glycerol was obtained from BDH, England. 
Crospovidone was purchased from 3B pharmaceutical (Wuhan) 
International Co. Ltd, China. Sodium starch glycolate was gifted from 
Samarra Drug Industries (SDI), Iraq. Microcrystalline cellulose 
(Avicel PH 102) was gifted from al-Hekma Drug Industry, Jordan. 
Magnesium stearate was obtained from Riedel-De-Haen AG Seelze, 
Germany. Lactose and Hydrochloric acid were obtained from Labort, 
Mumbai, India. Polyvinyl alcohol, disodium hydrogen phosphate and 
potassium dihydrogen phosphate were obtained from SD fine–Chem 
limited, Mumbai, India. 
Methods 
Preparation of piroxicam microsponge  
Piroxicam micro sponges were prepared by quasi emulsion solvent 
diffusion method. In this method the internal phase consists of 
Eudragit (RS100, RL100, S100) dissolved in an organic solvent 
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(ethanol, dichloromethane (DCM) and methanol) then glycerol was 
added as plasticizer and followed by the addition of piroxicam under 
ultra sonication at 35̊C for  15 min. The internal phase was then 
poured into the external phase (0.05% polyvinyl alcohol in distal 
water) after one hour of stirring by mechanical stirrer (from Copley 
scientific, UK) at a rate of 500 rotations per minute (r. p. m); the 
micro sponges were formed due to the removal of organic solvent 
from the system. The micro sponges were filtered and dried at 40 °C 
for overnight. The composition of each microsponge formulation is 
shown in table 1. The fabricated microsponge were evaluated for 
production yield, loading efficiency, particle size and in vitro 
dissolution studies were done for the formulas having the best 
physical properties. Formula of highest release profile was further 
subjected to kinetic release model, FTIR, differential scanning 
calorimetry, X-ray diffractometry and scanning electron 
microscopy. 
Determination of production yield  
The production yield of the Microsponge was determined by 
calculating accurately the initial weight of the raw materials and the 
last weight of the Microsponge obtained after drying [6].  
 
 


























PF1 0.3 0.1 ---- ---- ---- 2.5 ---- 100 0.5 500 1 
PF2 0.6 0.1 ---- ---- ---- 2.5 ---- 100 0.5 500 1 
PF3 0.9 0.1 ---- ---- ---- 2.5 ---- 100 0.5 500 1 
PF4 0.3 ---- 0.1 ---- ---- 2.5 ---- 100 0.5 500 1 
PF5 0.6 ---- 0.1 ---- ---- 2.5 ---- 100 0.5 500 1 
PF6 0.9 ---- 0.1 ---- ---- 2.5 ---- 100 0.5 500 1 
PF7 0.3 ---- ---- 0.1 ---- 2.5 ---- 100 0.5 500 1 
PF8 0.6 ---- ---- 0.1 ---- 2.5 ---- 100 0.5 500 1 
PF9 0.9 ---- ---- 0.1 ---- 2.5 ---- 100 0.5 500 1 
PF 10 1.2 0.1 ---- ---- ---- 2.5 ---- 100 0.5 500 1 
PF 11 0.9 0.1 ---- ---- 2.5 ---- ---- 100 0.5 500 1 
PF 12 0.9 0.1 ---- ---- ----- ---- 2.5 100 0.5 500 1 
PF 13 0.9 0.1 ---- ---- ---- 5 ---- 100 0.5 500 1 
PF 14 0.9 0.1 ---- ---- ---- 7.5 ---- 100 0.5 500 1 
  Values were kept constant ٭
 
Determination of loading efficiency  
The drug content in the micro sponges was determined using a UV 
spectrophotometer from EMC LAB, GmbH, Germany. A sample of PIR 
microsponge (10 mg) was dissolved in 1000 ml of 0.1 N HCL (pH 
1.2). The solutions were subsequently diluted (if needed) suitably 
with the same solution and spectrophotometric absorbance was 
taken at the corresponding λ max of PIR. The drug content was 
calculated from the calibration curve and expressed as the loading 
efficiency [7].  
 
Particle size measurement  
The average particle size of PIR loaded micro sponges was 
determined by using an optical microscope from Olympus, Japan. 
Minute quantities of microsponges were spread on a clean glass 
slide and the average particle size was calculated by measuring 100 
particles of each batch [8]. 
 
Where: Dav is the average diameter of particles (μm), n is the 
number of particles per group, and d is the middle value (μm).  
In vitro dissolution study 
The in-vitro drug release study was carried out using dissolution 
testing apparatus paddle type (Copley dissolution 8000, Copley 
scientific, UK). Sample equivalent to (10 mg) of piroxicam is used. 
The dissolution test was performed using 900 ml of 0.1N HCL (pH 
1.2). The formulas were rotated at 50 r. p. m at 37±0.5 °C. The 
samples were collected at specified time intervals (5, 10, 15, 20, 25, 
30, 45, 60, 90 and 120 min) and immediately replaced with fresh 
dissolution medium to maintain the sink conditions, the sample was 
filtered through a 0.45 Millipore filter, then the filtrate was diluted 
(if necessary) with the same dissolution media. The absorbance of 
the filtrate was measured by a UV spectrophotometer at the 
corresponding λmax of piroxicam [9].  
Fourier transform infrared (FTIR)  
FTIR is an extremely powerful technique in detecting and evaluating 
any possible chemical interaction between piroxicam and any 
excipient during microsponge preparation. Moreover, molecular 
level characterization of microsponge can also be obtained by 
performing FTIR studies FTIR spectra of the pure PIR and the 
selected microsponge formula were recorded on potassium bromide 
disc using an FTIR spectrometer (FTIR-8300 Shimadzu, Japan) to 
ascertain compatibility [10].  
Differential scanning calorimetry (DSC)  
DSC can be used to evaluate the physical properties of drugs and 
also to determine the compatibility of the drug and excipients. 
Thermal analysis using DSC (thermo-analyzer from LENSEIS) was 
carried out on pure PIR and the prepared PIR microsponge. 
Accurately weighed samples (10 mg) were loaded into aluminum 
pans and sealed. Samples were run at a heating rate of 5 °C/min. over 
a temperature range 0-300 °C in an atmosphere of nitrogen [11]. 
X-ray powder diffractometry (PXRD) 
To verify the physical state of drug in pure state and the changes in 
the crystallinity of the PIR microsponge formulation, the PXRD study 
was carried out by using X-ray diffractometer from Shimadzu 
Company, Japan. The voltage of 40 Kv and a current of 40 mA of the 
generator were applied with Cu as the tube anode material. The 
samples of pure drug and the optimum microsponge formula were 
analyzed between 5 ° to 60 ° [12]. 
Scanning electron microscope (SEM) 
For morphology and surface topography, the selected microsponge 
can be coated with gold–palladium under an argon atmosphere at 
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room temperature and then the surface morphology of the 
microsponges can be studied by scanning electron microscopy from 
(Angstrom Advanced Inc., USA) [13].  
Formulation of PIR Microsponge tablets  
The selected PIR microsponge are further fabricated into a tablet 
dosage form in order to be administered orally, Different formulas as 
shown in table (2) were formulated to show the effect of different 
type and concentration of additive material on the properties of PIR 
microsponge tablet (as well as pure PIR tablet prepared from the 
same additive of the selected formula) using a direct compression 
method as way of tablet preparation. In this method accurately 
weighed quantities of active ingredient (PIR microsponge 
corresponding to 10 mg of piroxicam) and the calculated excipients 
(except Mg stearate) were mixed for 10 min using mortar and pestle 
after which the remaining material was added and blended for 
another 2 min. The final mixtures are compressed using a single 
punch tablet machine.  
Pre-compression parameters of PIR microsponge tablet powder  
Measurement of angle of repose 
Using the fixed funnel method, the angle of repose of the prepared 
PIR microsponge tablet powder was determined. The following 
procedure was used to measure the angle of repose, a funnel with 
the end of the stem cut perpendicular to the axis of symmetry is 
secured with its tip at a given height (h) (which is maintained at 
approximately 2-4 cm from the tip of the powder pile in order to 
minimize the impact of the falling powder on the tip of the cone), 
above graph paper placed on a flat horizontal surface. The powders 
were carefully poured through the funnel until the apex of the 
conical pile so formed just reached the tip of the funnel; the graph 
paper was not allowed to vibrate. The tan of the angle was calculated 
after measuring the radius and the height of the cone of the powders 
using the following equation [14]. 
 
Where θ is the angle of repose, the results were given as a mean±SD. 
of triplicate. 
Evaluation of the prepared PIR microsponge tablets 
Tablet hardness test  
The hardness (force required to break a tablet by diametrical 
compression) of all the prepared PIR microsponge tablets was 
measured using a Monsanto hardness tester. Since the minimum 
practical hardness that provides adequate mechanical resistance is 
not less than 3 kg, so the hardness of the entire prepared tablet 
should be kept as possible above this limitation. Results are 
expressed as a mean±SD of triplicate. 
Tablet friability  
The friability test was done for the PIR microsponge tablets using 
friabilator apparatus for 4 min at 25 r. p. m. The procedure can be 
summarized by taking ten pre-cleaned tablets, weighing them all 
together then placing them inside the tester. After their revolution, 
they were deducted and weighed again. The friability was calculated 
as the percent weight loss. If the reduction in the total mass of the 
tablets is more than 1%, the tablets fail in the friability test, 
 
the 
friability percent of the tablet was calculated using the following 
equation [16]. 


















PF15 10.2 ----- 3.4 ---- ---- 1 155.4 
PF16 10.2 ----- 6.8 ---- ---- 1 152 
PF17 10.2 ----- ---- 3.4 ---- 1 155.4 
PF18 10.2 ----- ---- 6.8 --- 1 152 
PF19 10.2 ----- 6.8 ---- 4.25 1 147.75 
PF20 10.2 ----- 6.8 ----- 8.5 1 143.5 
PF21 ---- 10 6.8 ---- 8.5 1 143.7 
 
 
Disintegration time test (DT) 
The disintegration test was carried out for the prepared PIR 
microsponge tablets by using the USP disintegration apparatus from 
Erwaka, ZT 3-4, Germany, the basket rack assembly containing six 
open-ended tubes and 10-mesh screen on the bottom was used, 
these six tubes are filled with 0.1NHCL (pH 1.2). The time in minute 
required for the complete passing of all fragments of the tablet is 
recorded as a disintegration time of the tablet [17].  
Content uniformity  
Five tablets were weighed individually and powdered. The powder 
equivalent to 10 mg of PIR was weighed and dissolved in 10 ml of 
0.1 NHCL (pH1.2) and volume was adjusted to 1000 ml with the 
same solution. Then the solution was filtered and from this solution 
1 ml was taken and diluted with 0.1N HCL (pH1.2) in 100 ml 
standard volumetric flask. The amount of drug present in each tablet 
was determined spectrophotometrically at the λmax 
In vitro drug dissolution study  
of PIR using a 
UV–spectrophotometer. The percentage content was determined 
using standard calibration curve equation.  
In vitro dissolution studies of the promising PIR microsponge tablets 
and the ordinary prepared PIR tablet formulations were performed 
according to USP XXIII Type-II dissolution apparatus employing a 
paddle stirrer at 50 r. p. m using 900 ml of 0.1N HCL (pH 1.2) at 
37±0.5 °C as dissolution medium. One tablet was used in each test; 
the aliquot volume of the dissolution medium (5 ml) was withdrawn 
at specific time intervals (5, 10, 15, 20, 25, 30, 45, 60, 90 and 120 
min) and replaced immediately with an equal volume of fresh 
medium. The samples were filtered through 0.45 µm millipore filter 
and analyzed for drug content by measuring the absorbance at 
piroxicam λmax
Kinetic model of drug release 
 using an ultraviolet-visible spectrophotometer. Drug 
concentration was calculated from the standard calibration curve 
and expressed as a percent of a cumulative drug release [18]. 
The release profile of piroxicam from both optimum microsponge 
and the selected PIR microsponge tablet were examined to show the 
best kinetic release model which has the highest R2
Accelerated stability studies 
 value that 
interpret such profile; these models include zero order, first order, 
Higuchi model, Hixson-Crowell model and Korsmeyer–Peppas 
model.  
The optimum formula was subjected to the accelerated stability test. 
The test was performed for 16 w duration and three various 
temperatures 40 °C, 50 °C, and 60 °C. After that, the samples were 
taken at 14 d interval and examined for their PIR content 
spectrophotometrically at corresponding piroxicam λmax. 
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Statistical analysis 
The results of the experiments are given as a mean of triplicate 
samples±standard deviation and were analyzed according to the 
one-way analysis of variance (ANOVA) to determine if the 
differences are statistically significant at (P<0.05) using Microsoft 
office excel 2010. 
RESULTS AND DISCUSSION  
Formulation of piroxicam microsponge 
Piroxicam loaded microsponges were prepared by quasi-emulsion 
solvent diffusion method from different types of polymer (Eudragit 
RS100, RL100 and S100) which are biologically inert, non-irritating, 
non-mutagenic, non-allergenic, non-toxic and non-biodegradable 
polymers. As a result, the human body cannot convert them into 
other substances or break them down, so when these polymers 
administered orally, they are excreted unchanged with the 
remaining food [19]. Because of its simplicity and reproducibility, 
quasi-emulsion solvent diffusion method was used for the 
preparation of microsponges. Moreover, it has the advantage of 
avoiding solvent toxicity [20]. The Production yield of all formulas 
lies between (51.67-96.33), all formulas have an acceptable loading 
efficiency ranged from (85.18-98), there is a significance difference 
(p<0.05) between three types of polymer in the case of production 
yield and loading efficiency. Regarding the particle size of the 
prepared microsponge the mean lie between (70.34 µm-40.33 µm), 
the results are depicted in the table (3). 
Effect of formulation variables on the production yield and the 
loading efficiency  
A real fact illustrates that the production yields and loading efficiency, 
enhanced by increasing the drug: polymer ratio. Since in the higher 
drug: polymer ratios, the available polymer can encapsulate more 
amount of drug. The highest loading efficiency, the greater amount of 
drug was encapsulated [21]. An increment in the drug to polymer ratio 
resulted in the formation of drug crystals over particle surfaces. It is 
easily deducible from the earlier hypothesis that at a higher drug: 
polymer ratios, more drugs will reach the surface of the nascent micro 
sponges being dissolved in the solvents during diffusion. Moreover, as 
the diffusion of solvents becomes slower with the increase in drug: 
polymer ratio, so there was more time for the formation of drug 
crystals [22, 23]. The result showed a significant (p<0.05) increase in 
the production yield and loading efficiency. Its secretariat to mention 
that the further increment in the drug polymer ratio will lead to 
unfavorable results. These findings characterized by decreasing in 
the production yield and the loading efficiency, this is may be due to 
the improper amount of polymer available for coating the high 
concentration of drug [24].  
It remains to recall that the difference in the viscosity of the three 
types of polymer used may lead produce a dissimilar result of 
microsponge properties. 
Concerning solvent type it was found that ethanol significantly 
(p<0.05) increased the loading efficiency when compared to 
dichloromethane and methanol. This may be due to the higher 
boiling point of ethanol (78.4 °C) compared to dichloromethane (40 
°C) and methanol (64.7 °C), so ethanol would evaporate more slowly 
than dichloromethane. The lower organic solvent evaporation rate led 
to a lower solvent front kinetic energy, which accordingly decreased 
the rate of diffusion of the solvent from the inner to the outer phase, so 
increasing the chance for loading the drug into the polymer [25].  
It was clearly visible that upon an increment of ethanol volume, the 
loading efficiency will be increased; this result may be related to the 
higher solubilization of drug in ethanol. The high volume of the inner 
phase solvent resulted in the uniform mixing of drug and solvent 
which consequently lead to higher loading efficiency [26]. It was 
hypothesized that with the increase in a solvent ratio, the 
precipitation of polymer solution droplets gradually became slower, 
allowing more time for solvent diffusion and subsequent deposition of 
drug crystals on the particle surface [22]. Moreover, the higher volume 
of ethanol yields more spongy and porous microsponge. The increased 
amount of ethanol also causes the precipitation of the drug at the 
periphery of the microsponge. This may enhance the drug release [27]. 
The result suggests that the amount of ethanol need to be controlled 
within an appropriate range to affect not only the formation of quasi-
emulsion droplets at the initial stage but also the solidification of drug 
and polymer in the droplets. The good micro sponges were produced 
when 5 ml of ethanol was used. 
Effect of formulation variable on particle size  
It was observed that as the ratio of drug to polymer was increased, 
the particle size decreased. This result may be attributed to two 
aspects. First, this could probably be due to the fact that in high drug 
to polymer ratio, the amount of polymer available per microsponge 
was comparatively less. Probably in high drug-polymer ratios, less 
polymer amounts surround the drug and reducing the thickness of 
polymer wall and micro sponges with smaller size were obtained 
[28]. Secondly, the least viscous polymer solution that results from 
minimum polymer fraction. This decrement in viscosity facilitates 
the breaking of an emulsion into smaller droplets resulting in micro 
sponges with teeny particle size [29]. It is worthwhile to mention 
that the production of smaller microsponge may lead to enhance the 
probability of entrapping the drug molecule since a larger surface 
area are available and more active place are ready to absorb drug 
resulting in a preferable loading efficiency[30]. 
However the particle size was slightly increased (non-significant 
p>0.05) when ethanol is used, since the other two organic solvents 
have the high solvent evaporation rate led to a higher solvent front 
kinetic energy, which accordingly raise the rate of diffusion of the 
solvent from the inner to the outer phase (the critical parameter 
determining the particle size), so this will lead to a smaller particle [31].  
Regarding the volume of ethanol used, it was concluded that as the 
volume increased, a smaller microsponge globules are formed. These 
results may be related to the reduction in the viscosity of the 
internal phase. 
 
Table 3: Properties of the prepared microsponge 
Code Production yield٭ (%) Loading Efficiency٭ (%) Particle size means٭ (µm) 
PF1 61.67±1.44 66.98±3.39 66.33±1.52 
PF2 69.52±.82 64.37±1.95 59.33±2.51 
PF3 82.00±3 88.33±1.45 53.33±1.52 
PF 4 51.67±3.81 70.62±1.26 69.33±1 
PF 5 54.76±2.18 78.80±1.5 64.00±.57 
PF 6 78.67±1.15 82.52±1.61 57.67±2.08 
PF 7 53.33±1.44 58.18±2.7 70.34±1.15 
PF 8 61.43±1.42 73.28±1.11 66.67±1.69 
PF 9 69.00±1 76.91±.72 58.57±2.64 
PF10 79.72±1.73 79.99±2.75 51±2.02 
PF11 75.67±.57 80.84±1.96 51.17±1.52 
PF12 78.33±2.08 83.72±1.23 53.33±1.15 
PF13 96.33±2.51 98±.77 40.33±1.15 
PF14 82.00±2.64 94.81±.42 45.20±1.05 
  All values are expressed as mean±SD٭ 
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In vitro drug dissolution study  
The dissolution testing was done for the formulas that have a 
preferable production yield, loading efficiency and the smaller 
particle size and also for pure PIR powder, so PF13 and PF14 are 
examined. The drug release profile of the microsponge formulation 
showed that cumulative percent drug release was high in the 1st half 
hour (fig. 1). Burst release was observed, which could be due to the 
surface adsorbed drug and the well-known porous nature of micro 
sponges, the pores providing channels for drug release [32]. 
Formula (PF13) Acquire superior dissolution rate in comparison 
with other formulas and with pure drug, this may be attributed to 
the fact that the reduction of drug particle size caused an increase in 
the surface area and consequently enhanced the contact between 
particles and dissolution medium. The obtained results are in good 
accordance with Noyes–Whitney equation which states that the 
diminished particle size lead to an increased dissolution rate [33], 
also it must be remembered that a little amount of Eudragit RS100 
form a smaller micro sponges, and hence shorten the path length in 
which the drug molecule has to traverse. Another explanation 
suggested that the low amount of Eudragit RS100 lead to enhance 
the amount of drug close to surface with a simultaneous reduction in 
the amount of drug getting entrapped in the polymer matrix occurs. 
This leads to raise in the rate of drug release from the microsponges. 
These findings are in accordance with that obtained by Harsh et al. 
[34]. In the recent year united state food and drug administration 
provide a guideline in a comparison between the dissolution profiles 
of pharmaceutical product using similarity and dissimilarity factor (f 
2, f 1), in which f1 values lower than 15 (0–15) and f2 values greater 
than 50 (50–100) mean similarity of the dissolution profiles [35]. In 
the case of PIR microsponge formula (PF13) reported as a test and 
the pure drug as a reference, it was shown that PF13 and pure drug 
profiles are not similar as f1 value was higher than 15, whereas their 
f2 value was more than 100. Moreover, the amount of drug released 
at 2 min and the time required to reach 80% of drug released were 
also studied as shown in the table (4). PF13 was determined as the 
optimum formula because it had the higher dissolution rate, 
acceptable production yield, high loading efficiency, and small 
particle size, so it was subjected to further investigation. The release 
of PIR from microsponge PF13 mainly flows Hixon-Crowell release 
kinetic as their (R2
 
) gave a higher value. It was found that the 
mechanism of drug release is non Fickian diffusion as the release 
exponent "n" value is more than 0.5 and less than 1 which is the 
standard value for declaring non Fickian release behavior (fig. 2). 
Table 4: Parameter of drug release profile of PIR microsponge (PF13) 
Code % Released at 2 (min) Time to reach 80% of drug released (min) Dissimilarity factor Similarity factor 
PF 13 14 40 19 167 
 
 
Fig. 1: Dissolution profile of the prepared microsponge 
formulas and pure PIR powder 
 
 
Fig. 2: Release kinetic of the prepared PIR microsponge (PF13) 
 
Fourier transforms infrared analysis  
The FTIR spectra of PIR were shown in fig. (3 a), the main 
characteristic peak of PIR was the secondary amine N-H stretching 
which appeared at 3338 cm-1. It has been reported that piroxicam 
has two inter convertible crystalline forms, namely the needle and 
cubic forms. The IR absorption peaks at 1634 cm-1 and 1629 cm-1 are 
assigned to the stretching of the amide carbonyl groups of the needle 
form and the cubic form respectively, the peak at 1529 cm-1 is due to 
the stretching of the second amide band for both crystalline forms of 
piroxicam. In the present study, the peak at 1629.55 cm-1
The PIR spectra also exhibited other characteristic peaks like, C=N 
stretching vibration of pyridyl nitrogen assigned at 1577.49 cm
 was found 
in the IR spectrum of piroxicam, suggesting that the cubic form of 
piroxicam was used. 
-1, 
C=C stretching of pyridine ring at 1531.2 cm-1, C=C stretching of 
aromatic ring at 1434.78 cm-1, C-N stretching at 1349.79 cm-1, C-O 
stretching at 1214.93 cm-1, S(=O)2 stretching at 1149.37 cm-1,-SO2-N 
stretching at 1064 cm-1, aromatic CH bending at 875.52 cm-1, ortho-
disubstituted phenyl at 773.89 cm-1 and C-S stretching at 690.39 cm-
1 [36, 37]. Eudragit RS100 pattern (fig. 3b) showed an ester C=O 
stretching peak around 1724 cm-1. The pattern of the selected 
microsponge formula (fig. 3c) showed band at 3336.88 cm-1, which 
was related to the N-H stretching and all the original peaks of the 
pure drug remained without changing, the existence of 1629 cm-1
Differential scanning calorimetry (DSC) 
 
indicates that the piroxicam was fixed in the cubic polymorphic form 
and no interaction with accidents occurred. Specific changes in IR 
spectra are not very clear. This could be due to variations in the 
resonance structure, rotation of a part of a molecule or certain bond, 
so it was can concluded that there is no interaction between 
piroxicam: Eudragit RS100 after evaporation of the solvent. Similar 
results were obtained by Adibkia et al. [38]. 
According to the DSC thermograms (fig. 4a), pure PIR manifest a 
sharp characteristic endothermic peak at 201 ◦
X-ray powder diffractometry  
C corresponding to 
the melting point of the drug in the crystalline form, which are the 
same as reported by other study [39]. Through the study of the DSC 
curve of PIR microsponge (PIR: Eudragit RS100), the thermogram of 
the selected microsponge formula (fig. 4b) showed that the drug 
remained in its crystalline form and also there was no interaction 
between the drug and the remaining materials. The drug peak 
passes away mainly may be due to the lower amount of polymer 
used in the preparation of PIR microsponge (FP13) in comparison to 
the amount of drug (the drug to polymer ratio used in FP13 is 9:1). 
Such results revealed that there is no interaction between PIR and 
another constituent, indicating that the fabrication process used for 
the preparation did not change the nature of the drug in 
microsponges. It has remained to recall that the shifting of the 
endothermic peak to the left may be related to the decrement in the 
crystallinity of the PIR microsponge. 
The selected PIR microsponge and the pure PIR alone were tested 
using X-ray powder diffraction device. The characteristic peaks of 
piroxicam appeared in the 2θ range (0–60o). The pure drug (fig. 5a) 
exhibits its characteristic diffraction peaks at various diffraction 
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angles indicating the presence of crystallinity. On the other hand, the 
examination of the selected PIR microsponge formula shown that 
there is a clear change in the physical properties of the compound in 
terms of degree of crystallization indicating the crystalline nature of 
the drug and this result agreed with that obtained from DSC study. 
Upon inspection the chart of the selected microsponge formula (fig. 
5b), there was an interesting reduction in the intensity of the peaks 
with the survival of most of them with no appearance of new 
diffraction peaks which rules out any chemical interaction between 
the components, suggesting that the overall structure of the 
compound was not changed and it was identical to what were 
obtained from the DSC and FTIR. These findings suggested that 




Fig. 3a: FTIR spectra of pure PIR powder 
 
 
Fig. 3b: FTIR of eudragit RS100 
 
 
Fig. 3c: FTIR of the prepared PIR microsponge (PF 13) 
 
 
Fig. 4a: DSC thermogram of pure PIR powder 
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Fig. 4b: DSC thermogram of the prepared microsponge (PF13) 
 
 
Fig. 5a: X-ray diffraction of a pure PIR powder 
 
 
Fig. 5b: X-ray diffraction of the prepared microsponge (PF13) 
 
Scanning electron microscope (SEM) 
The surface of the preferable of piroxicam microsponge formula 
(PF13) was studied by scanning electron microscopy, it was shown 
(fig. 6) That's the fabricated microsponge formula have a spherical 
shape with sponge-like structure, the surface topography reveals 
that PIR microsponges contained tiny pores. The pores were induced 
by the diffusion of the inner phase solvent (ethanol) from the surface 
of the microparticles. The appearance of the particles was such that 
they were termed microsponges. Studying the outer surface reveal 
the formation of drug crystals over the particle surfaces because the 
optimum microsponge formulas prepared with higher 
drug/polymer ratio (9:1). The reason behind this result is easily 
explained from the earlier guess-work in which at higher 
drug/polymer ratios, more drugs will reach the surface of the 
microsponges being dissolved in the solvents during diffusion. 
Anyway, the presence of microchannels leads to the more 
penetration of dissolution medium and consequently the more 
dissolution rate and the better drug release. It is clear from the fig. 
that microsponges have a spherical shape and containing orifices. 
With the formation of spherical particles, it can be expected to 
improve powder properties of the drug, such as flowability and 
compressibility.
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Fig. 6: Scanning electron microscope of the prepared microsponge (PF13) 
 
Piroxicam microsponge tablet formulation  
After selection of best PIR microsponge formula, this formula was 
further incorporated into a tablet dosage form using (CP, SSG) as a 
disintegrant, lactose as diluent and Mg stearate as a lubricating agent, 
and then these materials are fabricated into tablet intended to be 
administered orally by the direct compression method. Piroxicam 
microsponge tablets were formulated using direct compression method 
since it is rapid, convenient, uncomplicated, less time consuming, 
appropriate for the production of tablets containing sensitive moisture 
ingredient, less equipment used and consequently more reduction in the 
production cost [40]. It was assumed that the microsponges might 
possess a unique compression property due to their matrix or sponge-
like structure which can easily be compressed by direct compression and 
applied by the oral route for systemic administration [41]. 
Variable affect on the flow properties of the tablet powder  
Since the flowability of the powder mixture are important for the 
content uniformity of the drug in the tablet, the flow properties of 
the powder mixture were estimated before compression of the 
tablet. It is worthwhile to mention that crospovidone have a perfect 
Carr’s index and angle of repose values when compared with the 
sodium starch glycolate; this may be related to the difference in the 
particle size, shape and its distribution [42]. Upon addition of 
microcrystalline cellulose (Avicel PH102) an improvement in the 
flow properties was showed, since it has a bigger particle size and 
the particle shape is more spherical. Microcrystalline cellulose 
(MCC) is a good excipient for direct compression processing. MCC 
has inherently high compactability due to its plastic deformation and 
limited elastic recovery. It usually provides good dispersion and 
uniform mixing with drugs. The results were illustrated in table (5). 
Variable affect on the physical properties of the prepared tablet  
The hardness parameter shows a range from (4-5.5) with no 
significant difference (p>0.05), also the friability value are within the 
accepted limit, this would result in a good mechanical strength. The 
disintegrants have the major function to oppose the efficiency of the 
tablet compactness and the physical forces that act under 
compression to form the tablet. An effective disintegration process is 
required to release the medication rapidly. Ideally, the disintegrating 
agent should cause the tablet to disrupt into powder particles from 
which the tablet was prepared. It is observed that, when CP is used 
as a disintegrant, tablets disintegrate rapidly within less time as 
compared to other tablets prepared using sodium starch glycolate. 
The superior disintegrating action of crospovidone is attributed to 
its wicking and swelling property in the presence of water. The 
sponge-like structure of CP is believed to contribute to its wicking 
action with subsequent swelling to aid disintegration. The results 
were shown in the table (5). The addition of CP had no adverse effect 
on tablet hardness, so the tablet of high hardness and rapid 
disintegration can be obtained by CP; however, it is important to 
mention that CP also maintains disintegration time of the tablet 
unchanged over a long period of time [43]. 
MCC showed excellent compact hardness, those related to the 
hydrogen bonding that it plays a big role in compact hardness. 
Hydrogen bonding is important because MCC undergoes 
significant plastic deformation during compression, bringing an 
extremely large surface area into close contact and facilitating 
hydrogen bond formation between the plastically deformed, 
adjacent cellulose particles. In addition, the existence of moisture 
within the porous structure of MCC acts as an internal lubricant, 
this facilitates slippage and flow within the individual 
microcrystals during plastic deformation, which enforces the 
formation of hydrogen bond bridges and gives better compatibility 
and hardness for MCC [44]. 
Although MCC is water insoluble material, but it has the ability to 
draw fluid into the tablet lattice by capillary action, the table, then 
swells when contact with water and hence, MCC acts as disintegrant, 
it is known that microcrystalline cellulose present binding and 
disintegrating characteristics, therefore it acts as an auxiliary tablet 
disintegrant because of its water-absorbing capacity [45]. 
 
Table 5: Pre and post compression parameter of PIR microsponge tablet and pure PIR tablet 
Code Carr index٭ (%) Angle of repose٭ Hardness٭ Friability٭ (%) Disintegration time٭ (min) 
PF15 15.45±1.23 28.39±1.1 4.56±0.57 0.62±0.07 4.33±0.57 
PF16 12.85±0.62 24.94±0.92 4.2±0.1 0.58±0.1 3.66±0.59 
PF17 16.25±1.73 30.73±0.53 4.67±0.14 0.47±0.08 4.66±1.52 
PF18 15.42±1.52 26.05±0.33 5.23±0.05 0.56±0.05 4.26±0.75 
PF19 12.59±0.42 23.87±0.79 4.45±0.06 0.45±0.05 4.33±1.56 
PF20 9.74±0.83 19.76±1.01 4.73±0.15 0.34±0.04 3.66±1.15 
PF21 24.73±0.74 37.88±0.68 3.93±0.25 0.87±0.01 5.5±1.32 
 All values are expressed as mean±SD٭
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Content uniformity  
All the prepared tablets had an acceptable content of PIR meeting 
the requirement of the USP.  
In vitro dissolution studies 
The release profile of the prepared PIR microsponge (PF16, PF18, 
PF20) and pure PIR tablet (PF21) were tested using 0.1N HCl (pH 
1.2) which represents the media of the stomach where the 
dissolution of the prepared PIR microsponge tablets may occur. As 
shown in fig. (7), PF20 have the highest release value as compared 
with the other formulas in which it have the lowest time to provide 
85% of drug release along with the maximum percent of liberated 
drug in 2 min. Crospovidone demonstrated a more rapid dissolution 
rate for the model drugs, irrespective of their aqueous solubilities 
since crospovidone is a nonionic disintegrant, so no any ionic 
interaction occurs between it and the drug moiety, unlike the anionic 
disintegrants sodium starch glycolate [46]. Moreover crospovidone 
have particle size range (25-40) µm providing a surface area of 
about 1.4 m2/gram while SSG have particle size (~50 µm) with 
surface area about 0.2 m2
 
/gram, these huge difference in the surface 
area along with solvent like chemistry resulting in high interfacial 
activity that the rapid release of drug from crospovidone as 
compared with SSG [47]. Of fairness, we must not forget that MMC may 
represent the suitable additive in the case of preparing an oral tablet 
containing poor water soluble drug by direct compression method [48]. 
 
Fig. 7: Dissolution profile of prepared microsponges tablet and pure PIR tablet 
 
Table 6: Parameter of drug release profile of PIR microsponge (PF20) 
Code Zero-order First-order Higuchi-model Hixson-Crowell Korsmeyer-pepers 
 R K2 Ro K2 R1 K2 RH K2 Rs n 2 
PF20 0.70 0.99 0.31 -0.31 0.92 10.75 0.93 0.41 0.50 0.934 
 
Kinetic modeling of drug release from the tablet  
The releases profile of PF20 (CP4%+MMC 5%) was further studied to 
obtain the kinetic model of liberated PIR from the prepared formula. 
As shown in the table (6) the determination coefficients (R2
The degradation of PIR microsponge tablet followed first-order 
kinetic since a straight line resulted from the plotting the logarithm 
of percent drug remaining versus time. The degradation rate 
constant at three different temperature was estimated from the 
slope of each line as mentioned in the table (7). Arrhenius plot was 
constructed in order to estimate the degradation rate constant (K
), the in 
vitro release data were in favor of Hixon–Crowell model. The value of n 
were>0.5 and<1 indicating non Fickian (anomalous) transport. 
Accelerated stability studies  
25) 
at 25 °C which was found to equal to 4.36 × 10-4 w-1
T
. This value was 
further utilized to calculate expire date of the selected PIR 






is the time required for a drug to lose 10% of its 
potency, expire date of PIR microsponge tablet was found to be 
240.54 w or about 4.6 y. The dissolution profile of the stored tablets 
did not show a significant change (P>0.05) after 16 w. The 
inspection of tablets also did not reveal any layer separation, 
lamination, capping or any change in their physical properties. 
Table 7: Degradation rate constants (K) for PIR microsponge tablets at different temperatures 
Temperature (°C) K (week-1) 
40 1.612 x 10-3 
50 2.763 x 10
60 
-3 
7.139 x 10-3 
 
CONCLUSION  
Piroxicam can be successfully formulated into a microsponge using 
quasi-solvent diffusion method, formula containing piroxicam and 
Eudragit RS100 in a ratio of 9:1, using ethanol as inner solvent in a 
volume of 5 ml and the volume of polyvinyl alcohol solution (100 
ml) represent the most preferable one in which it have suitable 
production yield, loading efficiency and smaller particle size, the rate 
of dissolution are highly increased as compared with pure PIR. 
Furthermore, fabrication of piroxicam microsponge into tablet 
dosage form by direct compression method using a crospovidone as 
a disintegrant along with microcrystalline cellulose have 
appropriate physical properties and a valuable dissolution profile, 
the release of piroxicam from both microsponge powder and from 
tablet follow Hixon–Crowell model and these formulas delivered 
their active ingredient by non Fickian diffusion.  
So the overall result suggests that piroxicam microsponge tablet 
could be a promising way to enhance their solubility and dissolution 
profile also improvement of the unfavorable flow properties. 
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